Compare BGSI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | STOK |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2025 | 2019 |
| Metric | BGSI | STOK |
|---|---|---|
| Price | $81.67 | $24.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $146.71 | $46.46 |
| AVG Volume (30 Days) | 26.3K | ★ 782.2K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $29.53 | N/A |
| Revenue Next Year | $8.35 | $39.98 |
| P/E Ratio | $231.07 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $75.42 | $20.32 |
| 52 Week High | $183.10 | $40.22 |
| Indicator | BGSI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 45.36 |
| Support Level | $75.42 | $24.21 |
| Resistance Level | $91.90 | $33.61 |
| Average True Range (ATR) | 2.50 | 1.33 |
| MACD | 0.83 | 0.35 |
| Stochastic Oscillator | 74.62 | 56.19 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. The Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.